Vaccinex to Present Promising Biomarker Data, Unveil Enlarged Phase 2B Alzheimer's Trial Plans
VCNX has more than doubled off its 52-week low of $0.252.
Summary
Vaccinex announced it will present promising new biomarker data from its Phase 1b/2 trial of pepinemab for early Alzheimer's disease. This data supports the company's plans for an enlarged randomized Phase 2B SIGNAL-AD study. The presentation is scheduled for July 13, 2026, at the Alzheimer's Association International Conference. For a micro-cap clinical-stage biotech, advancing a lead candidate into an enlarged Phase 2B trial with supportive biomarker data is a highly material positive development. The market will be looking for specific details from the July 13th presentation.
At the time of this announcement, VCNX was trading at $1.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.25 to $1.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.